Literature DB >> 27485115

Clinical significance of β2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma.

Kengo Takahashi1, Kyoichi Kaira2, Akira Shimizu3, Taisuke Sato1, Norifumi Takahashi1, Hiroomi Ogawa1, Daisuke Yoshinari1, Takehiko Yokobori4, Takayuki Asao5, Izumi Takeyoshi1, Tetsunari Oyama6.   

Abstract

The β2-adrenergic receptor (β2-AR) is highly expressed in various human neoplasms and has been considered a novel therapeutic target of cancer treatment. However, the clinicopathological significance of β2-AR expression in patients with gastric cancer (GC) remains unclear. The aim of this study was to explore β2-AR expression and its prognostic significance. A total of 331 patients with surgically resected GC were evaluated. Tumor sections were stained immunohistochemically for β2-AR. And, we confirmed β2-AR expression in the GC cell lines by Western blot. β2-AR was highly expressed in 30.5 % of GC patients. Expression was significantly associated with age, T factor, tumor differentiation, histology of non-signet cells, lymphatic permeation, and vascular invasion. And, all the GC cell lines expressed β2-AR. On univariate analysis, age, disease stage, T factor, N factor, lymphatic permeation, vascular invasion, and β2-AR expression were significantly associated with overall survival. Although the multivariate analysis did not indicate that β2-AR expression was independently prognostic of survival, high-level β2-AR expression was associated with significantly poorer survival of GC patients with well or moderately differentiated tumors. β2-AR expression was a significant predictor of tumor aggressiveness in, and poorer survival of, patients with GC.

Entities:  

Keywords:  Gastric cancer; Immunohistochemistry; Prognosis; β2-adrenergic receptor; β2-blocker

Mesh:

Substances:

Year:  2016        PMID: 27485115     DOI: 10.1007/s13277-016-5139-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

2.  Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Authors:  Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-31       Impact factor: 44.544

3.  Association of single nucleotide polymorphisms of β2-adrenergic receptor gene with clinicopathological features of pancreatic carcinoma.

Authors:  Yu Wenjuan; Li Yujun; Yu Ceng
Journal:  Acta Histochem       Date:  2012-07-19       Impact factor: 2.479

4.  The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor.

Authors:  S Maudsley; K L Pierce; A M Zamah; W E Miller; S Ahn; Y Daaka; R J Lefkowitz; L M Luttrell
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

Review 5.  Current role of beta-blockers in the treatment of hypertension.

Authors:  Wilbert S Aronow
Journal:  Expert Opin Pharmacother       Date:  2010-04-28       Impact factor: 3.889

Review 6.  Epithelial-mesenchymal transition: implications in cancer progression and metastasis.

Authors:  L R Gomes; L F Terra; M C Sogayar; L Labriola
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

Review 7.  Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters.

Authors:  Frank Entschladen; Theodore L Drell; Kerstin Lang; Jan Joseph; Kurt S Zaenker
Journal:  Lancet Oncol       Date:  2004-04       Impact factor: 41.316

8.  The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.

Authors:  Dongtai Chen; Wei Xing; Jian Hong; Meibing Wang; Yang Huang; Cuizhen Zhu; Yunfei Yuan; Weian Zeng
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

9.  Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).

Authors:  Satoshi Matsusaka; Atsushi Nashimoto; Kazuhiro Nishikawa; Akira Miki; Hiroto Miwa; Kazuya Yamaguchi; Takaki Yoshikawa; Atsushi Ochiai; Satoshi Morita; Takeshi Sano; Yasuhiro Kodera; Yoshihiro Kakeji; Junichi Sakamoto; Shigetoyo Saji; Kazuhiro Yoshida
Journal:  Gastric Cancer       Date:  2016-07       Impact factor: 7.370

10.  Novel regulatory program for norepinephrine-induced epithelial-mesenchymal transition in gastric adenocarcinoma cell lines.

Authors:  Tao Shan; Xijuan Cui; Wei Li; Wanrun Lin; Yiming Li; Xi Chen; Tao Wu
Journal:  Cancer Sci       Date:  2014-06-18       Impact factor: 6.716

View more
  9 in total

Review 1.  Non-coding RNAs underlying chemoresistance in gastric cancer.

Authors:  Arash Poursheikhani; Zahra Bahmanpour; Ehsan Razmara; Ladan Mashouri; Mohammad Taheri; Dorsa Morshedi Rad; Hassan Yousefi; Amirreza Bitaraf; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2020-06-03       Impact factor: 6.730

2.  β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway.

Authors:  Ming-Bing Xiao; Dan-Dan Jin; Yu-Jie Jiao; Wen-Kai Ni; Jin-Xia Liu; Li-Shuai Qu; Cui-Hua Lu; Run-Zhou Ni; Feng Jiang; Wei-Chang Chen
Journal:  Mol Biol Rep       Date:  2018-10-10       Impact factor: 2.316

3.  Beta1- and Beta2-Adrenoceptors Expression Patterns in Human Non-small Cell Lung Cancer: Relationship with Cancer Histology.

Authors:  Marisa Coelho; Andrea Imperatori; Anna Maria Chiaravalli; Francesca Franzi; Massimo Castiglioni; Emanuela Rasini; Alessandra Luini; Massimiliano Legnaro; Franca Marino; Laura Ribeiro; Marco Cosentino
Journal:  J Neuroimmune Pharmacol       Date:  2019-10-16       Impact factor: 4.147

4.  Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis.

Authors:  Masahiro Koh; Tsuyoshi Takahashi; Yukinori Kurokawa; Teruyuki Kobayashi; Takuro Saito; Tomo Ishida; Satoshi Serada; Minoru Fujimoto; Tetsuji Naka; Noriko Wada; Kotaro Yamashita; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Kiyokazu Nakajima; Makoto Yamasaki; Hidetoshi Eguchi; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2021-03-29       Impact factor: 7.370

5.  Identification of aberrantly expressed long non-coding RNAs in stomach adenocarcinoma.

Authors:  Jianbin Gu; Yong Li; Liqiao Fan; Qun Zhao; Bibo Tan; Kelei Hua; Guobin Wu
Journal:  Oncotarget       Date:  2017-07-25

6.  Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma.

Authors:  Alina Maria Mehedințeanu; Veronica Sfredel; Puiu Olivian Stovicek; Michael Schenker; Georgică Costinel Târtea; Octavian Istrătoaie; Ana-Maria Ciurea; Cristin Constantin Vere
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

Review 7.  Emerging Roles of the Nervous System in Gastrointestinal Cancer Development.

Authors:  Chunhua Wan; Xiaoqin Yan; Baoying Hu; Xinhua Zhang
Journal:  Cancers (Basel)       Date:  2022-07-30       Impact factor: 6.575

8.  ADRB2 expression predicts the clinical outcomes and is associated with immune cells infiltration in lung adenocarcinoma.

Authors:  Lingyun Ji; Fei Xu; Jingtao Zhang; Ting Song; Weida Chen; Xi Yin; Qingqing Wang; Xiubao Chen; Xin Li; Minghao Guo; Zetao Chen
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

9.  The role of propranolol as a radiosensitizer in gastric cancer treatment.

Authors:  Xinhua Liao; Prakash Chaudhary; Guanglin Qiu; Xiangming Che; Lin Fan
Journal:  Drug Des Devel Ther       Date:  2018-03-28       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.